Thank you, Mr. Atamenko. It is a pleasure to have you testifying before us.
I had exactly the same experience yesterday. I was speaking to a bill in support of retirees who had lost part of their pension fund. I was introducing the bill for the second time. So I was at the witness table too. It is always a bit more nerve-racking than being on this side. So I congratulate you on having introduced this bill and for speaking to it at our meeting.
My main question is technical in nature—I feel that it is exactly as Mr. Easter was saying. When the bill says the analysis of potential harm to the export market, the first question that occurs to me is: what will be the criteria for deciding whether to allow or disallow the sale of new genetically modified seeds?
I completely agree with you in adding another analysis to the one dealing with the effects or lack of effects on human and animal health. That is being studied in other countries as well. I would like to know if you have thought about the criteria needed for that analysis that would lead us to conclude whether we could allow the product to be sold or not.